Im not sold on the accuracy,  but fintel shows tutes owning over 13.6M shares, up about 25% from end of q3.  Float shrinkage

And those tax sellers are going to want back in!  

Chil, I don't think Topline selling anymore since they'd have to file a Form 4 (over 10% owner).  I think they just did a one time eoy balancing of checkbook.  The sentiment of insider sells is/was the problem imo.  Anyone who purchased in last 8 months likely upside down creating mass tax sell-off and big time "shaking of the tree".   Sellers have to be running thin!!  8 weeks until Mark says "I told you so!!"

Shortie barely here
Paysign Short Interest Data

Have a good weekend!

IMO those who sold for tax purposes are chomping at bit to get back in. Late November sellers tripping over themselves already after 30-day wash sale rule

# of anylists: 5
Low price target: $6
High price target: $7.25
Mean price target: $6.65
Target vs Current: 122.4%

$6 PT without a whisper of PA

PAYS
Paysign initiated with a Buy at Lake Street
Lake Street initiated coverage of Paysign with a Buy rating and $6 price target. Paysign is a "market leader" in prepaid plasma donor incentive programs with 40% market share and two of the top three plasma donation center providers, notes the analyst, who calls this "a long-term growth market" given that there are several use cases for the extracted plasma. The firm "conservatively" estimates new donation center openings can grow at a 5% compound annual growth rate through 2026 with stable market share, equating to mid-single digit revenue growth potential from the plasma segment for Paysign, the analyst added.

They got big legs because they've been running alot!

The three largest PBMs have begun creating foreign corporate entities and moving certain operations abroad to avoid transparency and evade proposed PBM reforms.

Paysign has been an advocate for transparency within the pharmaceutical supply chain7, and the wider healthcare industry for years, and we are encouraged to see these bi-partisan committee and federal agency investigations expose evidence proving PBMs responsible for driving prescription price inflation, costing taxpayer dollars, and lowering the overall quality of care for patients. We greatly value our role helping pharmaceutical companies increase patient access to life-saving medications and therapies.

My pea brain thinks Trump's actions towards the PBM's is a huge feather in our cap and we're perfectly aligned to take the reigns.  Would this not throw the PBM's under the bus and open the doors for us (PAYS) to save the day!?!?

https://paysign.com/five-takeaways-from-government-investigations-on-pbms/




https://fortune.com/2024/12/17/donald-trump-drug-prices-healthcare-pharmacy-benefit-managers-press-conference/

I'm very excited for the next couple years.  And the END of this one!

Not a subscriber to this and it was previously locked.  Able to read now...

https://seekingalpha.com/article/4738925-paysign-stock-leader-fintech-healthcare-payments-durable-profitable-growth#comments

Rounded out my position.  May still go lower, but daaaaammmmmnnnn these are hard to pass up!!  Turning this lemon into lemonade.  Mark made a boo boo and got ahead of his skis.  No doubt he saw higher pps in the cards.  That higher pps is imminent IMO

A Rule 10b5-1 plan can be set up to execute trades with minimum or maximum prices or with price targets that change over time, so long as the price targets or the method for determining the price targets is set forth in the plan.

If only there was a minimum set!  

Couldn't agree more JP

Chil, i got no clue re man with the plan, but i think it ends in June.  Stay strong brother.   This thing's gettin' where it's gettin' regardless.  No way pps stays here long.  Big 2025 on horizon imo

Yes, but the sellers of November probably chomping at bit to get back in once wash sale expires.  Might see improvement b4 year end.  My optimism shining through.....

Nah, fully loaded.  Sitting on my hands until tax selling slows

Broadly speaking, up to 1.2M shares over 12 month period.  I believe that started in June with a 3 month "cooling down period"

Right on cue.  Market doesn't seemed phased.  Onward!

Larger offers being taken down

Me too.  Will Mark's "plan" put us in our place?

Finally showing some good vibes.  Just in time for Mark's 100k share dump ffs

But it'll sure be fun to witness 

Target vs current pps OVER 100%

This thing is going to bounce like a mofo

On a brighter note.  Tute holdings starting to update.  During q3 Blackrock purchases 2,266,668 shares, Kestra Advisory has new stake at 402k shares, ameriprise financial with a new stake of 262k shares.  Up to 13.35M total institutional holdings which does not include Topline's 6 million shares.

I believe Mark will be selling about 100k per month for many months.  The plan is in motion.  

Very temporary imo.   Catalyst in motion!  Pharma Karma

We're getting a nice view of the pharma trajectory.   As we prove ourselves I only expect our share of market to grow.   It's quite the opportunity to start a long position at these current pps.  My shares are in the vault

That's what we wanted to hear!  Nicely done Paysign!

SOLID!!!

Barrington Research analyst Gary Prestopino maintains PaySign (NASDAQ: PAYS) with a Outperform and maintains $7 price target

I didn't realize I needed more, but here I am ADDING. 

Agreed!  And I doubt Mark would wait a decade to set up such a plan if he expects pps to be flat.  I believe he expects quite the contrary

Joule Financial LLC acquired a new stake in shares of Paysign, Inc. (NASDAQ:PAYS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 402,783 shares of the company's stock

The insider specifies the number of shares to sell, the prices, and the dates in advance. The plan is created during an open trading window when the insider doesn't have any material nonpublic information (MNPI). Once the plan is in place and a cooling-off period has passed, the trades are triggered

I'm not sure, but he might not have a choice: